The US Food and Drug Administration (FDA) has approved the Q-Pad and A1C Test, a unique menstrual pad that measures blood sugar levels using menstrual blood.

Developed by biotechnology company Qvin, this organic cotton pad collects blood for laboratory analysis and reveals average blood sugar levels over three weeks through the A1C biomarker.

CEO and co-founder of Qvin Sara Naseri noted the massive potential of menstrual blood, stating, “There is a lot of clinically relevant information in this bodily fluid that comes every month.”

This innovative, non-invasive approach allows women to gain regular insights into their health, making it a huge advancement in personal health monitoring.

But the Q-Pad’s capabilities don’t stop there. Experts believe this technology could also be adapted to diagnose conditions like HPV and endometriosis, broadening its impact on women’s health care.

As the Q-Pad hits the market, it will give women the opportunity to turn menstrual care into an important tool for health management. Qvin provides test results as an online service.

“A smartphone with internet access is recommended for optimal use of our service and to view your lab reports,” its website said.

Their logo, “Empowering women. Period,” highlights the potential of often-overlooked biological materials for diagnostics, paving the way for further research into how menstrual blood can improve health monitoring.

With this new tool, women can take a proactive approach to their health, making the monthly cycle not just a time for personal care but also an opportunity for meaningful health insights. The future of menstrual health is looking brighter than ever.